The invention relates to a method of treating a hyperproliferative disorder in a non-human mammal comprising administering a therapeutic combination as a combined formulation or by alternation to the non-human mammal, wherein the therapeutic combination comprises a therapeutically effective amount of comprising GDC-0032 having the structure: and a therapeutically effective amount of a chemotherapeutic agent selected from 5-FU, docetaxel, eribulin, gemcitabine, GDC-0973, GDC-0623, paclitaxel, fulvestrant, pertuzumab, trastuzumab emtansine, and trastuzumaband a chemotherapeutic agent which is letrozole, in the manufacture of a medicament for use in the treatment of cancer by separate, simultaneous or sequential administration of a therapeutically effective amount of the GDC-0032 and the chemotherapeutic agent, wherein the cancer is selected from breast, cervical, colon, endometrial, gastric, glioma, lung, melanoma, ovarian, pancreatic, and prostate.
